Revolution Medicines is trading up 10.2% at $220.00 after RASONQUE generated $197.6 million in net product revenue in its first five weeks, far above analysts’ roughly $24 million revenue expectation. - Benzinga reported EPS of $(1.90), beating its $(2.42) estimate. - The company reported third-quarter results on November 4 after the regular-session close; it had scheduled its results and webcast for after market close. - The move outpaced the broad-market rally, supporting an earnings-driven explanation rather than market sentiment alone.